Profil
Martin Erixon formerly worked at Hamlet BioPharma AB, as Chief Executive Officer from 2022 to 2023, Hamlet BioPharma AB, as Chief Executive Officer from 2023 to 2025, Gambro AB, as Manager-Research & Development Project, and Tetra Pak AB, as Manager-Research & Development Project from 2011 to 2022.
Mr. Erixon received his doctorate degree in 2007 from the University of Lund.
Anciens postes connus de Martin Erixon
| Sociétés | Poste | Fin |
|---|---|---|
| HAMLET PHARMA AB (PUBL) | Directeur Général | 18/02/2025 |
| HAMLET PHARMA AB (PUBL) | Directeur Général | 01/10/2023 |
Tetra Pak AB
Tetra Pak AB Pulp & PaperProcess Industries Manufactures laminated paperboard materials and related packaging products | Corporate Officer/Principal | 01/06/2022 |
Gambro AB
Gambro AB Medical SpecialtiesHealth Technology Develops and manufactures dialysis equipment and blood purification products | Corporate Officer/Principal | - |
Formation de Martin Erixon
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Gambro AB
Gambro AB Medical SpecialtiesHealth Technology Develops and manufactures dialysis equipment and blood purification products | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tetra Pak AB
Tetra Pak AB Pulp & PaperProcess Industries Manufactures laminated paperboard materials and related packaging products | Process Industries |
Hamlet BioPharma AB
Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
















